帕博利珠单抗治疗PD-L1阳性晚期宫颈癌:KEYNOTE-028 Ib期试验结果
KEYNOTE-028 Ib期试验评估帕博利珠单抗在PD-L1阳性晚期宫颈癌队列的安全性和疗效。24例患者接受帕博利珠单抗10 mg/kg每2周治疗,客观缓解率为17%(95% CI 5%至37%),4例(17%)达确认部分缓解,中位缓解持续时间5.4个月(4.1至7.5个月)。治疗相关不良事件发生率为75%,仅皮疹(21%)和发热(17%)发生率≥10%,5例发生3级治疗相关不良事件,无4级事件或死亡。
要点
- 帕博利珠单抗在PD-L1阳性晚期宫颈癌中客观缓解率17%,4例部分缓解。
- 中位缓解持续时间5.4个月(范围4.1至7.5个月)。
- 安全性与其他肿瘤类型一致,无4级治疗相关不良事件或死亡。
核心结论
- 在PD-L1阳性晚期宫颈癌患者中,帕博利珠单抗显示出抗肿瘤活性,安全性与在其他肿瘤类型中观察到的特征一致。
研究设计与样本
- KEYNOTE-028 Ib期试验(NCT02054806)宫颈癌队列,纳入24例PD-L1阳性晚期宫颈癌患者。
- 患者接受帕博利珠单抗10 mg/kg每2周治疗,最长24个月。
- 主要终点为研究者根据RECIST v1.1评估的客观缓解率,安全性为次要终点。
主要发现
- 客观缓解率为17%(95% CI 5%至37%),4例(17%)达确认部分缓解,3例(13%)疾病稳定。
- 4例部分缓解患者的中位缓解持续时间为5.4个月(范围4.1至7.5个月)。
- 18例(75%)发生治疗相关不良事件,仅皮疹(5例,21%)和发热(4例,17%)发生率≥10%。
- 5例发生3级治疗相关不良事件,未观察到4级治疗相关不良事件或死亡。
关键数值与推荐
- 客观缓解率17%(95% CI 5%至37%)。
- 确认部分缓解4例(17%),疾病稳定3例(13%)。
- 中位缓解持续时间5.4个月(范围4.1至7.5个月)。
- 治疗相关不良事件18例(75%),3级事件5例。
临床怎么用
- 对于PD-L1阳性晚期宫颈癌患者,帕博利珠单抗可作为具有抗肿瘤活性且安全性可控的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. Methods Patients were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. The primary end point was overall response rate per Response Evaluation Criteria in Solid Tumors, version 1.1, by investigator review. Safety was a secondary end point. Results Twenty-four patients were enrolled in the cervical cancer cohort. The median age was 42 years (range, 26 to 62 years), 22 patients (92%) had received prior radiation therapy, and 15 patients (63%) had received two or more lines of therapy, including bevacizumab (10 of 24 patients), for advanced disease. At the data cutoff, median follow-up duration was 11.0 months (range, 1.3 to 32.2 months). Overall response rate was 17% (95% CI, 5% to 37%); four patients (17%) achieved a confirmed partial response, and three patients (13%) had stable disease. Median duration of response for the four patients who achieved a partial response was 5.4 months (4.1 to 7.5 months). Treatment related adverse events (AEs) were experienced by 18 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred in ≥ 10% of patients. Five patients experienced grade 3 treatment-related AEs. No grade 4 treatment-related AEs or deaths were observed. Conclusion In patients with programmed death ligand 1-positive advanced cervical cancer, pembrolizumab demonstrated antitumor activity and exhibited a safety profile consistent with that seen in other tumor types.
引用
- Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017. PMID: 29095678. doi:10.1200/JCO.2017.74.5471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。